Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02665065 · ClinicalTrials.gov registry record · Phase 3
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
A Phase 3 study of Acute Myeloid Leukemia and Acute Myelogenous Leukemia, sponsored by Actinium Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 153
- Enrollment target
- 20
- Study locations
NCT02665065 is a Phase 3 study of Acute Myeloid Leukemia and Acute Myelogenous Leukemia that is active but no longer recruiting, run by Actinium Pharmaceuticals. The registered enrollment target is 153 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (33% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT02665065, a Phase 3 study of Acute Myeloid Leukemia and Acute Myelogenous Leukemia, is active but no longer recruiting, sponsored by Actinium Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 153 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia (AML).
Conditions Studied
Interventions
- DRUG Iomab-B
- DRUG Conventional Care
- PROCEDURE HCT
Study Locations (20)
New York
- Roswell Park Cancer Institute - Buffalo
- Weill Cornell Medicine - New York
- Memorial Sloan Kettering Cancer Center - New York
- Stony Brook University - Stony Brook
Ohio
- University Hospital of Cleveland Seidman Cancer Center - Cleveland
- The Ohio State University Comprehensive Cancer Center - Columbus
Texas
- Baylor Charles A. Sammons Cancer Center - Dallas
- MD Anderson Cancer Center - Houston
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Connecticut
- Yale Cancer Center - New Haven
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Florida
- Mayo Clinic - Jacksonville
Illinois
- Loyola University Medical Center - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2016-06 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02665065
The ClinicalTrials.gov registry entry for NCT02665065 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (33% higher). The listed sponsor is Actinium Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Iomab-B is the first listed.
NCT02665065 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT02665065 about?
NCT02665065 is a clinical study titled "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia". The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute...
What is the current status of trial NCT02665065?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 153 participants. The study started on 2016-06. Estimated completion is 2026-12.
What conditions does trial NCT02665065 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Leukemia, Myeloid, Acute, AML, Bone Marrow Transplant.
What interventions are being tested in trial NCT02665065?
The interventions under investigation include: Iomab-B (DRUG), Conventional Care (DRUG), HCT (PROCEDURE).
Who is sponsoring clinical trial NCT02665065?
This trial is sponsored by Actinium Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02665065 being conducted?
This trial has 20 study locations across Arizona, Connecticut, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RECRUITING · Phase 3
-
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RECRUITING · Phase 3
-
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
ACTIVE NOT RECRUITING · Phase 3
-
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 3
-
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.